Abstract
Background: There are growing evidence that indicate a relation between diabetic microangiopathy and cardiovascular disease with different mechanism.
Objective: To investigate the association of diabetic retinopathy (DR) with the risk of cardiovascular disease (CVD) in type 2 diabetic patients.
Methods: 180 type 2 diabetic patients who were free of CVD at baseline were enrolled. Patients were classified according to fundoscopy to no diabetic retinopathy (NDR), non proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). CVD risk at 10 years was estimated using the UK Prospective Diabetes Study risk engine and patients were classified as high risk (>20%), moderate risk (10-20%) and low risk (<10%).
Results: Prevalence of DR was 30.5%. Risk of CVD was significantly higher in PDR vs NDR (18.7±10.0% vs. 11.3±8.4%, p= 0.01) .The prevalence of NPDR (32% vs. 17.8%, p=0.002) and PDR (20% vs. 4.1%, p=0.04) was more in high risk group for CVD in comparison with low risk group for CVD. After adjustment for traditional risk factor for CVD, the risk for CVD remained markedly increased in the presence of DR.
Conclusion: DR is associated with estimated risk of CVD in type 2 diabetic patients.
Keywords: Retinopathy, cardiovascular disease, diabetes, UKPDS risk score.
Current Diabetes Reviews
Title:Is There any Correlation Between Diabetic Retinopathy and Risk of Cardiovascular Disease?
Volume: 13 Issue: 1
Author(s): Nasser Shoeibi and Shokoufeh Bonakdaran
Affiliation:
Keywords: Retinopathy, cardiovascular disease, diabetes, UKPDS risk score.
Abstract: Background: There are growing evidence that indicate a relation between diabetic microangiopathy and cardiovascular disease with different mechanism.
Objective: To investigate the association of diabetic retinopathy (DR) with the risk of cardiovascular disease (CVD) in type 2 diabetic patients.
Methods: 180 type 2 diabetic patients who were free of CVD at baseline were enrolled. Patients were classified according to fundoscopy to no diabetic retinopathy (NDR), non proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). CVD risk at 10 years was estimated using the UK Prospective Diabetes Study risk engine and patients were classified as high risk (>20%), moderate risk (10-20%) and low risk (<10%).
Results: Prevalence of DR was 30.5%. Risk of CVD was significantly higher in PDR vs NDR (18.7±10.0% vs. 11.3±8.4%, p= 0.01) .The prevalence of NPDR (32% vs. 17.8%, p=0.002) and PDR (20% vs. 4.1%, p=0.04) was more in high risk group for CVD in comparison with low risk group for CVD. After adjustment for traditional risk factor for CVD, the risk for CVD remained markedly increased in the presence of DR.
Conclusion: DR is associated with estimated risk of CVD in type 2 diabetic patients.
Export Options
About this article
Cite this article as:
Shoeibi Nasser and Bonakdaran Shokoufeh, Is There any Correlation Between Diabetic Retinopathy and Risk of Cardiovascular Disease?, Current Diabetes Reviews 2017; 13 (1) . https://dx.doi.org/10.2174/1573399812666151012115355
DOI https://dx.doi.org/10.2174/1573399812666151012115355 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Magnetomotive Molecular Nanoprobes
Current Medicinal Chemistry Ezetimibe and Reactive Oxygen Species
Current Vascular Pharmacology Use and Safety of Calcium Channel Blockers in Obstetrics
Current Medicinal Chemistry Inhibition of mTOR Signaling by Quercetin in Cancer Treatment and Prevention
Anti-Cancer Agents in Medicinal Chemistry Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment
Current Vascular Pharmacology Stroke as a Consequence of Sleep Apnea: Epidemiology, Pathophysiology and Treatment Strategies
Current Respiratory Medicine Reviews Controversies on HDL: Should it be a Target Biomarker in Patients with Lipid Disorders?
Current Vascular Pharmacology Glycaemic Control in Cardiac Surgery Patients: a Double-Edged Sword
Current Vascular Pharmacology Structure, Production and Function of Erythropoietin: Implications for Therapeutical Use in Cardiovascular Disease
Current Medicinal Chemistry Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications
Current Medicinal Chemistry Cardiac Oxidative Stress and Inflammatory Cytokines Response after Myocardial Infarction
Current Vascular Pharmacology The Importance of Gender Differences in the Diagnosis and Management of Cardiovascular Disease
Current Pharmaceutical Design Fontan Circulation Might be Associated with Peripartum Cardiomyopathy: A Review of Mechanistic and Clinical Aspects
Current Cardiology Reviews NPY Y1 and Y5 Receptor Selective Antagonists as Anti-Obesity Drugs
Current Topics in Medicinal Chemistry Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Current Pharmaceutical Design The Pathophysiology of Uric Acid in Relation to Cardiovascular Disease
Current Cardiology Reviews QSAR Modeling for the Antimalarial Activity of 1,4-Naphthoquinonyl Derivatives as Potential Antimalarial Agents
Current Computer-Aided Drug Design Integrative Health Services in School Health Clinics
Adolescent Psychiatry Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes?
Current Pharmaceutical Design